Cryopyrin-Associated Periodic Syndrome Medication Savings with TheDrugClub
Members can check active-formulary eligibility and membership pricing for Cryopyrin-Associated Periodic Syndrome medications. A condition association alone does not establish coverage.
What Is Cryopyrin-Associated Periodic Syndrome?
Cryopyrin-Associated Periodic Syndrome is a medical condition that may require prescription treatment. Consult a healthcare professional about appropriate options.
Managing Cryopyrin-Associated Periodic Syndrome with TheDrugClub
Eligible medications linked to the active formulary may have no additional cost under listed supply, quantity, fill, and fulfillment limits. Other prescriptions may qualify for membership pricing. Confirm current terms before filling.
- Join TheDrugClub as a member
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available membership pricing
About Cryopyrin-Associated Periodic Syndrome
Cryopyrin-Associated Periodic Syndrome (CAPS) is a group of rare genetic inflammatory disorders causing recurrent fevers, rashes, and joint pain. Managing CAPS often requires specialized, high-cost medications. TheDrugClub offers a vital solution, helping members significantly reduce the cost of these essential prescriptions, ensuring access to the care you need without financial strain.
Cryopyrin-Associated Periodic Syndrome (CAPS) refers to a spectrum of inherited autoinflammatory diseases, including Familial Cold Autoinflammatory Syndrome (FCAS), Muckle-Wells Syndrome (MWS), and Chronic Infantile Neurological, Cutaneous, and Articular Syndrome (CINCA), also known as Neonatal-Onset Multisystem Inflammatory Disease (NOMID). These conditions are caused by mutations in the *NLRP3* gene, which leads to an overproduction of a key inflammatory protein called interleukin-1 beta (IL-1β).
Individuals with CAPS experience recurrent episodes of inflammation, often triggered by cold exposure in FCAS, but otherwise appearing spontaneously. Common symptoms across the spectrum include recurring fevers, a characteristic urticarial-like rash, and joint pain or swelling. More severe forms, like MWS and CINCA/NOMID, can involve chronic fatigue, eye inflammation, hearing loss, and neurological complications such as chronic aseptic meningitis and developmental delays. If left untreated, CAPS can lead to serious long-term damage, including kidney failure due to amyloidosis.
Treatment for CAPS primarily focuses on targeting the overactive IL-1β pathway. The most common and effective medications are IL-1 inhibitors, which are biologic drugs designed to block the action of IL-1β. These include:
- Anakinra (Kineret): An IL-1 receptor antagonist, typically administered daily by injection.
- Canakinumab (Ilaris): A monoclonal antibody that directly binds to IL-1β, usually given every 4-8 weeks by injection.
- Rilonacept (Arcalyst): An IL-
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.